Abstract:In recent years, the U.S. Food and Drug Administration (FDA) has approved Chimeric Antigen Receptor (CAR)-T cell therapy as a novel approach to treating hematological diseases, including multiple myeloma, large B-cell lymphoma, and B-cell acute lymphoblastic leukemia. Using the patient's genetically altered T-cells, this novel strategy precisely targets antigens linked to cancer. Even with the encouraging outcomes of using bi-specific chimeric antigen receptors to stop tumor antigen evasion, difficulties still arise, especially when dealing with solid tumors. There are several challenges because of the intricate interactions among many elements in the tumor microenvironment, such as immunosuppression, hypoxia, decreased T-cell infiltration, elevated reactive oxygen species, and the erratic nature of tumor-associated antigens. This study examines current efforts to find reliable tumor-associated antigens in an attempt to address issues impeding the efficacy of CAR-T treatment. The fundamental objective is to create CAR-T cells that are economical while being adapted to the distinct characteristics of the tumor microenvironment. By means of a comprehensive analysis of the course of the therapy, the study explores its potential therapeutic uses for a range of tumor types, including solid and hematological malignancies. This work not only sheds light on the enormous obstacles to obtaining precision medicine in cancer treatment, but it also advances our knowledge of the promise that the specific therapy has. The presented results open the door for future developments in the field and provide a nuanced viewpoint on the revolutionary role that the treatment has played in the contemporary cancer scene.

Advances of CAR-T cell immunotherapeutic targeting for malignant tumors of children

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Current progress in CAR-T cell therapy for tumor treatment

[Recent Research on Chimeric Antigen Receptor T Cells in Children with Refractory/relapsed Acute Lymphoblastic Leukemia].

Current state of CAR-T therapy for T-cell malignancies

Advances of CD19-directed Chimeric Antigen Receptor-Modified T Cells in Refractory/relapsed Acute Lymphoblastic Leukemia

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

CAR T-cells for pediatric solid tumors: where to go from here?

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Application of CAR-T Cell Immunotherapy in the Treatment of Hematological Malignancy

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Progress on CAR-T Cell Therapy for Hematological Malignancies

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Advances in CAR-T-cell therapy in T-cell malignancies

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Current Clinical Application of the CAR-T Cell Therapy

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES

From bench to bedside: the history and progress of CAR T cell therapy